Venous thromboembolism in recipients of antipsychotics: Incidence, mechanisms and management

CNS Drugs

Volumn 26, Issue 8, 2012, Pages 649-662

  Jönsson, Anna K ^a   Spigset, Olav ^b,c   Hägg, Staffan ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

adverse drug reactions.; antipsychotics; embolism; thromboembolism; thrombosis; venous thromboembolism

Indexed keywords

CARDIOLIPIN ANTIBODY; CHLORPROMAZINE; CLOZAPINE; FIRST GENERATION ANTIPSYCHOTIC AGENT; HALOPERIDOL; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHOLIPID ANTIBODY; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; SERTINDOLE; THIORIDAZINE; UNCLASSIFIED DRUG;

AUTOPSY; BODY WEIGHT; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HOSPITAL PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERPROLACTINEMIA; IMMOBILIZATION; LUNG EMBOLISM; META ANALYSIS (TOPIC); OBESITY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; INCIDENCE; PSYCHOTIC DISORDERS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84863682451     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11633920-000000000-00000     Document Type: Review

References (77)

1. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005 Mar 26-Apr 1; 365 (9465): 1163-74
2. Liem TK, Deloughery TG. First episode and recurrent venous thromboembolism: who is identifiably at risk? Semin Vasc Surg 2008 Sep; 21 (3): 132-8
3. Ageno W, Squizzato A, Garcia D, et al. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006 Oct; 32 (7): 651-8
4. Brehmer G, Ruckdeschel KT. Technic of the hibernation therapy [in German]. Dtsch Med Wochenschr 1953 Dec 11; 78 (50): 1724-5
5. Labhardt F. Technic, side effects and complications of largactil therapy [in German]. Schweiz Arch Neurol Psychiatr 1954; 73 (1-2): 338-45
6. Grahmann H, Suchenwirth R. Thrombosis hazard in chlorpromazine and reserpine therapy of endogenous psychoses [in German]. Nervenarzt 1959 May 20; 30 (5): 224-5
7. Hagg S, Bate A, Stahl M, et al. Associations between venous thromboembolism and antipsychotics: a study of theWHO database of adverse drug reactions. Drug Saf 2008; 31 (8): 685-94
8. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997 Nov; 8 (6): 671-7
9. Hagg S, Spigset O, Soderstro TG. Association of venous thromboembolism and clozapine. Lancet 2000 Apr 1; 355 (9210): 1155-6
10. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a casecontrol study. Lancet 2000 Oct 7; 356 (9237): 1219-23
11. Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000 Jun; 20 (3): 325-7
12. Parkin L, Skegg DC, Herbison GP, et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003 Dec; 12 (8): 647-52
13. Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004 Sep; 68 (9): 850-2
14. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005 Dec 12-26; 165 (22): 2677-82
15. Masopust J, Maly R, Urban A, et al. Antipsychotic drugs as a risk factor for venous thromboembolism. Int J Psychiatr Clin Pract 2006; 11 (3): 246-9
16. Lacut K, Le Gal G, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007 Dec; 21 (6): 643-50
17. Ray JG. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm Med 2008 Sep; 14 (5): 369-73
18. Jonsson AK, Brudin L, Ahlner J, et al. Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. Int Clin Psychopharmacol 2008 Sep; 23 (5): 263-8
19. Jonsson AK, Horvath-Puho E, Hagg S, et al. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol 2009; 1: 19-26
20. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001 Jul; 179: 63-6
21. Knudson JF, Kortepeter C, Dubitsky GM, et al. Antipsychotic drugs and venous thromboembolism [letter]. Lancet 2000 Jul 15; 356 (9225): 252-3
22. Wolstein J, Grohmann R, Ruther E, et al. Antipsychotic drugs and venous thromboembolism [letter]. Lancet 2000 Jul 15; 356 (9225): 252
23. Hag S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol 2003 Sep; 18 (5): 299-300
24. Maly R, Masopust J, Hosak L, et al. Four cases of venous thromboembolism associated with olanzapine. Psychiatry Clin Neurosci 2009 Feb; 63 (1): 116-8
25. Hag S, Jonsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf 2009 Sep; 8 (5): 537-47
26. Hag S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16 (11): 765-76
27. Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008 Oct 1; 65 (19): 1825-9
28. Maly R, Masopust J, Hosa L, et al. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci 2007; 62: 3-8
29. Van Neste EG, Verbruggen W, Leysen M. Deep venous thrombosis and pulmonary embolism in psychiatric settings. Eur J Psychiat 2009; 23 (1): 19-30
30. Toringhibel M, Adam T, Arghir OC, et al. Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male: case report and literature review. Pneumologia 2011 Apr-Jun; 60 (2): 82-4
31. Allenet B, Schmidlin S, Genty C, et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012 Jan; 21 (1): 42-8
32. Kleijer BC, Heerdink ER, Egberts TC, et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010 Oct; 30 (5): 526-30
33. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested casecontrol study. BMJ 2010; 341: c4245
34. Zhang R, Dong L, Shao F, et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 2011 Jul; 44 (5): 183-8
35. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005: 1-12
36. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007 May 14; 167 (9): 935-43
37. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010 Mar 1; 81 (5): 617-22
38. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005 Nov 5; 366 (9497): 1640-9
39. Gustafsson F, Kragelund CB, Torp-Pedersen C, et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005 Jan; 26 (1): 58-64
40. Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003 Jun 17; 107 (23 Suppl 1): I9-16
41. Hagg S, Lindblom Y, Mjorndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006 Mar; 21 (2): 93-8
42. Allison DB, Mentore JL, Heo M, et al. Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156 (11): 1686-96
43. Urban A, Masopust J, Maly R, et al. Prolactin as a factor for increased platelet aggregation. Neuro Endocrinol Lett 2007 Aug; 28 (4): 518-23
44. Wallaschofski H, Eigenthaler M, Kiefer M, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003 Oct; 23 (5): 479-83
45. Wallaschofski H, Donne M, Eigenthaler M, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001 Dec; 86 (12): 5912-9
46. Rousseau AM. Hyperprolactinemia and atypical antipsychotic therapy in a case of fatal thromboembolism. J Clin Psychopharmacol 2010 Dec; 30 (6): 734-5
47. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008 Mar; 22 (2 Suppl.): 70-5
48. Axelsson S, Hagg S, Eriksson AC, et al. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007 Aug; 34 (8): 775-80
49. Schedel A, Thornton S, Kluter H, et al. The effect of psychoactive drugs on in vitro platelet function. Transfus Med Hemother 2010; 37 (5): 293-8
50. Dietrich-Muszalska A, Rabe-Jablonska J, Olas B. The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro. World J Biol Psychiatry 2010 Mar; 11 (2 Pt 2): 293-9
51. Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, et al. The first-and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. World J Biol Psychiatry 2010 Mar; 11 (2 Pt 2): 268-75
52. De Clerck F, Somers Y, Mannaert E, et al. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther 2004 Aug; 26 (8): 1261-73
53. Masopust J, Maly R, Andrys C, et al. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011; 11: 2
54. Schwartz M, Rochas M, Toubi E, et al. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J Psychiatry Neurosci 1999 Sep; 24 (4): 351-2
55. Lillicrap MS, Wright G, Jones AC. Symptomatic antiphospholipid syndrome induced by chlorpromazine. Br J Rheumatol 1998 Mar; 37 (3): 346-7
56. Sairam S, Baethge BA, McNearney T. Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies. Clin Rheumatol 2003 Feb; 22 (1): 24-9
57. Ayuso J, Saiz Ruiz J. Neuroleptic-induced antinuclear antibodies. Eur Psychiatry 1996; 11 (7): 378-9
58. Canoso RT, de Oliveira RM, Nixon RA. Neurolepticassociated autoantibodies: a prevalence study. Biol Psychiatry 1990 Apr 15; 27 (8): 863-70
59. Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988 Apr; 27 (4): 272-5
60. Metzer WS, Canoso RT, Newton JE. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy. South Med J 1994 Feb; 87 (2): 190-2
61. Steen VD, Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum 1988 Jul; 31 (7): 923-6
62. el-Mallakh RS, Donaldson JO, Kranzler HR, et al. Phenothiazine-associated lupus anticoagulant and thrombotic disease. Psychosomatics 1988 Winter; 29 (1): 109-13
63. Davis S, Kern HB, Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 1994 Jun; 46 (2): 166-7
64. Shen H, Li R, Xiao H, et al. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J Psychiatr Res 2009 Mar; 43 (6): 615-9
65. Halacheva K, Dimova S, Tolev T, et al. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res 2009 Aug 30; 169 (1): 51-5
66. Firer M, Sirota P, Schild K, et al. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 1994 Jan; 14 (1): 73-8
67. ChengappaKN, CarpenterAB, KeshavanMS, et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 1991 Oct 1; 30 (7): 731-5
68. Roche-Bayard P, Rossi R, Mann JM, et al. Left pulmonary artery thrombosis in chlorpromazine-induced lupus [letter]. Chest 1990 Dec; 98 (6): 1545
69. Haidemenos A, Kontis D, Gazi A, et al. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007 Aug 15; 31 (6): 1289-96
70. Henderson DC, Copeland PM, Nguyen DD, et al. Homocysteine levels and glucose metabolism in non-obese, nondiabetic chronic schizophrenia. Acta Psychiatr Scand 2006 Feb; 113 (2): 121-5
71. Vuksan-Cusa B, Jakovljevic M, Sagud M, et al. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 2011 Aug 30; 189 (1): 21-5
72. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007 Jun; 131 (6): 872-84
73. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26 (3): 263-79
74. Reif A, Schneider MF, Kamolz S, et al. Homocysteinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients. J Neural Transm 2003 Dec; 110 (12): 1401-11
75. Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006 Oct; 32 (7): 716-23
76. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005 Oct; 94 (4): 750-9
77. De Hert M, Einfinger G, Scherpenberg E, et al. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int J Clin Pract 2010 Jul; 64 (8): 1109-15